Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Taiwan Stock Exchange launches 2024 overseas tour to attract global capital: Europe trip targets heavyweight investor institutions




LONDON, Feb. 26, 2024 /PRNewswire/ — The Taiwanese stock market showed robust performance in 2023, marked by significant turnover volume surges and price gains. Foreign investors notably reversed three consecutive years of net selling, recording net buying of over TWD 275.4 billion (USD 8.7 billion). On a mission to expand international funding sources in 2024, the Taiwan Stock Exchange (the “TWSE”) is expected to visit more than a dozen prominent institutional investors in Europe in March to further strengthen international investor relations.

Thanks to its solid fundamentals, good corporate governance, and the investment trend in artificial intelligence (AI), the TAIEX, the market value weighted index on the TWSE, rose by 26.8% in 2023, outperforming major international stock markets in the US and Europe. Its average daily turnover increased by 16.1% to TWD 281.2 billion (USD 8.9 billion), with its total market capitalization reaching TWD 56.84 trillion (USD 1.8 trillion).

Taiwan stocks continued to shine at the start of the Year of the Dragon, propelled by the robust fundamentals. Both the TAIEX and market capitalization reached record-highs consistently since the market resumed trading on February 15, after the Lunar New Year holidays. On February 26, the TAIEX reached the highest closing level so far at 18,948.05 and the total market capitalization soared to TWD 60.21 trillion (USD 1.9 trillion).

Although 2023 was a challenging year for Initial Public Offerings (IPOs) in most international markets, the TWSE continued to enhance the domestic financing environment, expand its exposure to the capital market, and actively encourage companies to list on the board. The TWSE attracted a record-high of 42 companies to apply for listing in 2023, the highest in the past decade. These efforts resulted in IPO companies raising a record total capital of TWD 33.76 billion (USD 1.07 billion).

The Taiwan stock market surged in 2023, driven by an unprecedented level of participation by domestic investors. Additionally, international funds turned their selling from 2019 to 2022 to a net buying of TWD 275.4 billion (USD 8.7 billion) last year. Market sentiments were bullish as the US Federal Reserve (the “Fed”) was expected to end its rate hike cycle, and the TWSE also demonstrated its appeal to international investors through various overseas roadshows, including visits to the US, Japan, and Singapore. From the start of 2024 through February 26, foreign investors continued their net buying at TWD 123.58 billion (USD 3.9 billion).

Foreign capital plays a decisive role in Taiwan stocks. According to the TWSE, as at the end of 2023, foreign capital from the UK and Europe accounted for more than 37% of the market value of Taiwan stocks, becoming a main source of international funds.

To underscore its commitment to deepening cooperation with European market participants and forging deeper relationships with investors, Chen-Shan Chang, Director-General of the Securities and Futures Bureau of the Financial Supervisory Commission, Taiwan’s capital markets regulatory body, and Sherman Lin, Chairman and CEO of the TWSE, will lead a delegation to Europe in early March. The team will visit key stakeholders, including more than a dozen prominent institutions such as stock exchanges, clearing houses, custodian banks, index companies, institutional investors with substantial holdings in Taiwan stocks, potential large investment institutions, major asset management companies, and financial service institutions.

The TWSE will arrange one-on-one meetings with institutional investors and financial market infrastructures in London, Luxembourg and Frankfurt, in order to provide updates on key information regarding the Taiwan securities market, highlighting the advantages and development prospects within the Taiwan stock market. The officials will address all questions and concerns to boost investor confidence and seek advice from the investors. Additionally, they will exchange ideas and explore potential cooperation opportunities with prominent European institutions.

“The TWSE will embark on a visit to London, marking the first such visit in seven years,” said Sherman Lin. “During the trip, the TWSE will also conduct in-person exchange activities with major European exchanges, such as London and Frankfurt, for the first time. The highly anticipated trip is of great significance to both sides and is expected to yield exciting outcomes.”

The TWSE also plans to hold an investment seminar in London, offering investors an efficient way to understand Taiwan’s capital market. This seminar will provide international investors with a valuable opportunity to delve into Taiwan’s booming financial ecosystem, exploring dynamic developments, innovative sectors and promising investment opportunities.

Overall, the TWSE’s visit aims to forge connections with prominent institutional investors and major European exchanges, showcasing the enormous opportunities of Taiwan’s capital market. It underscores Taiwan’s ongoing commitments to actively deepen international investor relations and promote securities investment measures for enhanced international cooperation.

About TWSE

The Taiwan Stock Exchange (the “TWSE”) started operations on February 9, 1962. The TWSE is responsible for operating and advancing Taiwan securities market. The TWSE’s primary business operations include listing, trading, settlement and surveillance. These comprise listing promotion and review, post-listing supervision and corporate governance, maintaining market trading and order, securities firms’ services, investor protection, clearing and settlement operations, safeguarding against market defaults and the monitoring of illegal transactions. The Exchange provides comprehensive services to the stock market.

View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading